DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02640118

Px-Lixi

CompletedPhase NA

The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects

The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects -a Delineation of Extrapancreatic Effects

Asset

Lixisenatide

Subcutaneous · GLP-1 agonist

Listed sites

0

Recruiting sites

—

Enrollment

24

actual

Study population

Diabetes (other / unspecified), Healthy volunteers

Key I/E criterion

•Healthy volunteers

Primary endpoint

•Postprandial glucose

Identifiers

Registered as

NCT IDNCT02640118
Org study IDH-15004078

Timeline

Milestones

Study first posted2015-12-28estimated
Last update posted2020-05-07actual
Study start2015-08 (month precision)
Primary completion2016-07actual (month precision)
Study completion2016-07actual (month precision)

Assets

Investigational agents

Lixisenatide

Study populations

Who this study enrolls

Diabetes (other / unspecified)Healthy volunteers

Eligibility

Who can enroll

Minimum age18 Years
Maximum age80 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

Pancreatectomised patients

•Caucasians above 18 years of age who have undergone total pancreatectomy
•Normal haemoglobin
•Informed consent Healthy subjects
•Normal fasting plasma glucose (FPG) and normal HbA1C (according to the World Health Organization (WHO) criteria)
•Normal haemoglobin
•Age above 18 years
•Informed consent

Exclusion criteria

Pancreatectomised patients

•Inflammatory bowel disease
•Operation within the last 3 months
•Ongoing chemotherapy or chemotherapy within the last 3 months
•Ostomy
•Nephropathy (serum creatinine >150 µM and/or albuminuria)
•Severe liver disease (serum alanine aminotransferase (ALAT) and/or serum aspartate aminotransferase (ASAT) >3×normal values)
•Pregnancy and/or breastfeeding
•Age above 80 years
•Any condition that the investigator feels would interfere with trial participation Healthy subjects
•Diabetes mellitus (DM)
•Prediabetes (impaired glucose tolerance and/or impaired FPG)
•First degree relatives with DM
•Inflammatory bowel disease
•Intestinal resection and/or ostomy
•Nephropathy (serum creatinine >150 µM and/or albuminuria
•Liver disease (ALAT and/or serum ASAT >2×normal values)
•Pregnancy and/or breastfeeding
•Age above 80 years
•Any condition that the investigator feels would interfere with trial participation

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
3
Other (unclassified)
2
Weight & body composition
1
Patient-reported / QoL
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint

resting energy expenditure (REE)

Time frame:-90,30,150 minutes

descriptive

Glycemic / diabetes

3 endpoints
Primary/protocol endpoint

PPG excursions measured as incremental area under curve (iAUC)

Time frame:-120,-45,-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes

Postprandial glucose

descriptive, improvement

Secondary/protocol endpoint

p-glucose mmol/L

Time frame:-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes

Postprandial glucose

descriptive, improvement

Secondary/protocol endpoint

p-C-peptide pmol/l

Time frame:-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes

C-peptide AUC

descriptive

Patient-reported / QoL

1 endpoint
Secondary/protocol endpoint

food intake and appetite

Time frame:at time 0,30,60,90,120,150,180 minutes

descriptive

Other (unclassified)

2 endpoints
Secondary/protocol endpoint/low confidence

differences in gastric emptying, measurement of s-paracetamol

Time frame:-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes

descriptive

Secondary/protocol endpoint/low confidence

glucagon, gastrin, cholecystokinin, GIP, GLP-1, oxyntomodulin

Time frame:-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.